Xuefu-Zhuyu Capsule for the Treatment of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

720 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-31

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

"Xuefu-Zhuyu capsule" (XFZY) is made from a classic Fangji "Xuefu-Zhuyu Decoction" in an ancient Chinese medical book "Yi Lin Gai Cuo" by Chinese physician Wang Qingren, which is the most representative formula for the treatment of "Qizhi-Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome). XFZY concludes 11 kinds of Chinese herbs: Danggui(Angelica sinensis), Honghua(Safflower Flower), Chishao(Paeoniae Radix Rubra), Shengdihuang(Radix Rehmanniae), Taoren(Peach Seed), Zhike(Fructus Aurantii), Jugeng(Platycodon grandiflorum), Chuanxiong(Rhizome of Chuanxiong), Chaihu(Radix Bupleuri), Chuanniuxi(Cyathula Officinalis),Gancao(liquorice).It is mainly used to treat "Qizhi-Xueyu Zheng", which includes the symptoms such as different types of pain, irritability or depression, insomnia, chest tightness, dark skin, lumps or masses in vitro or in vivo, petechiae on the tongue, and dark purple tongue. The purpose of the trial is to evaluate the efficacy and safety of XFZY in treating "Qizhi-Xueyu Zheng", and investigate the most suitable diseases of XFZY.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome.

NCT03091634

Qi Stagnation and Blood Stasis Syndrome

COMPLETED PHASE2

A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)

NCT02875639

Ischemic Heart Failure

UNKNOWN PHASE2

Clinical Evidence Based and TCM Phenotype Group Study of Zhilong Huoxue Tongyu Capsule in the Treatment of Stable Angina Pectoris of Coronary Heart Disease (Qi Deficiency and Blood Stasis Syndrome)

NCT06709638

Coronary Heart Disease (CHD)

ENROLLING_BY_INVITATION PHASE2

Effects of Yiqi Fuyuan Paste Formula in Chronic Fatigue Syndrome: A Randomized Double-Blind Controlled Clinical Trial.

NCT07320937

CFS

ENROLLING_BY_INVITATION NA

Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)

NCT00817024

Coronary Heart Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chinese Medicine Stable Coronary Heart Disease Chronic Insomnia Headache Endometriosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

XFZY group

2.4g (6 capsules) three times daily for 12 weeks

Group Type EXPERIMENTAL

Xuefu-Zhuyu Capsule

Intervention Type DRUG

treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.

conventional therapy

Intervention Type OTHER

conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.

Control group

2.4g (6 capsules) three times daily for 12 weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.

conventional therapy

Intervention Type OTHER

conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xuefu-Zhuyu Capsule

treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.

Intervention Type DRUG

placebo

treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.

Intervention Type DRUG

conventional therapy

conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet the diagnostic criteria of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome).
* Meet the diagnostic criteria of stable coronary heart disease, chronic insomnia, headache (Migraine without Aura and Tension-Type Headache ), or endometriosis, among which:

* the score of angina pectoris frequency domain in SAQ ≤ 80 points in the patients with stable coronary heart disease;
* Pittsburgh sleep quality index\> 10 points in patients with chronic insomnia;
* Patients with migraine without aura have 3 or more attacks per month within 3 months before enrollment;
* In patients with tension-Type headache, within 3 months before enrollment, the number of attack days per month is ≥ 2 days;
* The VAS score of the pain ≥ 40 points in patients with endometriosis;
* Patients with endometriosis diagnosed with any type of confirmed pathological reports(previous diagnosis is also possible).
* Patients were ≥18 and ≤75 years of age.
* Voluntarily provided written informed consent.

Exclusion Criteria

* Patients with acute myocardial infarction, rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia and other severe arrhythmias and severe cardiac and pulmonary insufficiency in the past 3 months
* Patients with acute cerebrovascular disease such as cerebral infarction and cerebral hemorrhage in the past 3 months;
* Those with poorly controlled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg after treatment);
* Patients with aortic dissection;
* Patients with abnormal liver and kidney function indicators (ALT, AST are 1.5 times greater than the upper limit of normal value, and Scr is greater than the upper limit of normal value);
* SAS≥70 points;
* SDS≥73 points;
* VAS≥80 points;
* Patients with severe primary heart, brain, liver, kidney, and hematopoietic diseases;
* Women during pregnancy and lactation;
* Those with cognitive impairment, consciousness impairment or mental illness, who cannot communicate normally;
* People with allergies, or those who are known to be allergic to the trial drug (including its components);
* Surgery(including intervention, radio frequency, etc.) during the past 4 weeks;
* Those with bleeding tendency;
* Those who suspect or have a history of alcohol or drug abuse;
* Participation in another trial in the past 1 month;
* Other circumstances judged by the researcher to be unsuitable for participation in the trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No